The role of in vitro methods as alternatives to animals in toxicity testing

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 1, 2014, Pages 67-79

  Anadón, Arturo ^a   Martínez, María Aranzazu ^a   Castellano, Victor ^a   Martínez Larrañaga, María Rosa ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Alternative of animal testing; in vitro testing; Integrated in vitro testing strategies; Mechanism mode of action; Metabolism characterization

Indexed keywords

BIOLOGICAL MARKER; CHEMICAL AGENT; DISSOLVED OXYGEN; ENDOTOXIN; PYROGEN;

ACCURACY; CARCINOGENICITY; CELL DENSITY; CELL DIFFERENTIATION; CELL GROWTH; CELLULAR STRESS RESPONSE; CHORIOALLANTOIS; COMPUTER MODEL; CYTOTOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENDOPLASMIC RETICULUM STRESS; ESCHERICHIA COLI; EXTRACELLULAR MATRIX; FIBROBLAST CULTURE; GENOMICS; GENOTOXICITY; HIGH THROUGHPUT SEQUENCING; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMULUS LYSATE TEST; LIVER TOXICITY; MAMMAL CELL; METABOLIC ACTIVATION; MUTAGENICITY; NANOTECHNOLOGY; NONHUMAN; OXIDATIVE STRESS; PHARMACEUTICS; PHOTOTOXICITY; PLASMA PROTEIN BINDING; PROTEOMICS; RELIABILITY; REPRODUCIBILITY; REPRODUCTIVE TOXICITY; REVERTANT; REVIEW; SALMONELLA TYPHIMURIUM; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; TRANSCRIPTOMICS; VALIDATION PROCESS;

ANIMAL TESTING ALTERNATIVES; ANIMALS; CELL LINE; HUMANS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TOXICITY TESTS;

EID: 84890349550     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.854329     Document Type: Review

References (50)

1. Roggen EL. In vitro toxicity testing in the twenty-first century. Front Pharmaco 2011;2(3):1-3
2. Russel WMS, Burch RL. The principles of humane experimental technique. London: Methuen, 1959. Available from: Http://altweb. jhsph.edu/pubs/books/ humane-exp/hettoc
3. Franco N, Olsson I. Scientists and the 3Rs: Attitudes to animal use in biomedical research and the effect of mandatory training in laboratory animal science. Lab Anim 2013;[Epub ahead of print
4. Kinsner-Ovaskainen A, Akkan Z, Casati S, et al. Overcoming barriers to validation of non-Animal partial. Replacement methods/integrated testing strategies: The report of an EPAA-ECVAM workshop. ATLA 2009;37:437-44
5. Kinsner-Ovaskainen A, Maxwell G, Kreysa J, et al. Report of the EPAA-ECVAM workshop on the validation of integrated testing strategies (ITS). Altern Lab Anim 2012;40(3):175-81
6. EPAA. Flash report: Integrated testing strategies workshop. 2011. Available from: Http://www.ec.europa.eu/enterprise/ epaa/2-Activities/2-3-comm- And-dissem/ its-flash-report.pdf
7. Berg N, De Wever B, Fuchs HW, et al. Toxicology in the 21st century-Working our way towards a visionary reality. Toxicol In Vitro 2011;25:874-81
8. Louisse J, Verwei M, Woutersen RA, et al. Toward in vitro biomarkers for developmental toxicity and their extrapolation to the in vivo situation. Expt Opin Drug Metab Toxicol 2012;8(1):11-27
9. NRC. Committee on Toxicity Testing and Assessment of Environmental Agents, Board of Environmental Studies and Toxicology, Institute for Laboratory Animal Research. Toxicity testing in the 21st century. A vision and a strategy. National Academies Press; Washington, DC: 2007
10. Valerio LG Jr. In silico toxicology for the pharmaceutical sciences. Toxicol Appl Pharmacol 2009;241:356-70
11. Blaauboer BJ, Barratt MD, Houston JB. ECVAM workshop report 37. ATLA 1999;27:539-77
12. Vink SR, Mikkers J, Bouwman T, et al. Use of read-Across and tiered exposure assessment in risk assessment under REACH-A case study on a phase-in substance. Reg Toxicol Pharmacol 2010;58:64-71
13. De Wever B, Fuchs HW, Gaca M, et al. Implementation challenges for designing Integrated In Vitro Testing Strategies (ITS) aiming at reducing and replacing animal experimentation. Toxicol In Vitro 2012;26:526-34
14. NRC. Committee on Applications of Toxicogenomic Technologies to Predictive Toxicology, Board of Environmental Studies and Toxicology, Board of Life Studies, Division of Earth and Life Studies. Applications of Toxicogenomic Technologies to Predictive Toxicology and Risk Assessment. National Academies Press; Washington, DC: 2007
15. van Vliet E. Current standing and future prospects for the technologies proposed to transform toxicity testing in the 2st century. ALTEX 2011;28(1):17-44
16. Hartung T. From alternative methods to a new toxicology. Eur J Pharm Biopharm 2011;77:338-49
17. Combes RD, Balls M. Integrated testing strategies for toxicity employing new and existing technologies. ATLA 2011;39:213-25
18. Spieldmann H, Balls M, Dupuy J, et al. Study on the UV filter chemical from Annex VII of European union directive 76/768/EEC, in the in vitro 3T3 NRU phototoxicity test. Altern Lab Anim 1998;26:679
19. Fentem JH, Archer GE, Balls M, et al. The ECVAM international validation study on in vitro test for skin corrosivity 2. Results and evaluation by the Management Teal. Toxicol In Vitro 1998;12:483-524
20. OECD. TG 405 ''Acute eye irritation/ corrosion'', adopted October 2nd 2002, including a supplement to TG 405 entitled. A sequential testing strategy for eye irritation and, corrosion. p. 9-13
21. OECD. TG 404 ''Acute dermal irritation/corrosion'', adopted April 24th 2002, including a supplement to TG 404 entitled. A sequential testing strategy for dermal irritation and, corrosion. p. 11-14
22. Djabari Z, Bauza E, Dal C, et al. The HET-CAM test combined with histological studies for better evaluation of active ingredient innocuity. Int J Tissue React 2002;24:117-21
23. Adler S, Basketter D, Creton S, et al. Alternative (non-Animal) methods for cosmetics testing: Current status and future prospects-2010. Arch Toxicol 2011;85(5):367-485
24. Bissell MJ, Rizki A, Mian IS. Tissue architecture: The ultimate regulator of breast epithelial function. Curr Opin Cell Biol 2003;15:753-62
25. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005;5:675-88
26. Cooper JF. Principles and applications of the limulus test for pyrogen in parenteral drugs. Bull Parent Drug Assoc 1975;3:127-33
27. OECD. Series on testing and assessment No. 88. ''Report from the workshop on integrated approaches to testing and assessment'' held in ITS. 2007
28. OECD. Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment, series on testing and assessment, No. 34. OECD; Paris: 2005
29. Balls M, Blaauboer BJ, Fentem JH, et al. Practical aspects of the validation of toxicity test procedures. The report and recommendations of ECVAM workshop 5. ATLA 1995;23:129-47
30. Hartung T, Bremer S, Casati S, et al. A modular approach to the ECVAM principles on test validity. Altern Lab Anim 2004;32:467-72
31. Anadón A, Martínez-Larrañaga MR, Castellano V. Chapter 55. Biomarkers in drug safety evaluation: European perspective. In: Biomarkers in toxicology. Gupta RC, editor. Elsevier/Academic Press; San Diego, CA, USA: 2014; p. 923-45
32. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2006;1:1-48
33. Krewski D, Andersen ME, Mantus E, Zeise L. Toxicity testing in the 21st century: Implications for human health risk assessment. Risk Anal 2009;29(4):474-9
34. Blaauboer BJ, Boekelheide K, Clewell HJ, et al. The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. ALTEX 2012;29(4):411-25
35. Eisenbrand G, Pool-Zobel B, Baker V, et al. Methods of in vitro toxicology. Food Chem Toxicol 2002;40:193-236
36. Basketter DA, Clewell H, Kimber I, et al. A roadmap for the development of alternative (non-Animal) methods for systemic toxicity testing. ALTEX 2012;29:3-91
37. Tralau T, Riebeling C, Pirow R, et al. Wind of change challenges toxicological regulators. Environ Health Perspect 2012;120(11):1489-94
38. Wilmes A, Limonciel A, Aschauer L, et al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J Proteomics 2013;79:180-94
39. Renwick AG, Lazarus NR. Human variability and non-cancer risk assessment-An analysis of the default uncertainty factor. Regul Toxicol Pharmacol 1998;27:3-20
40. Clewell HJ, Andersen ME, Blaauboer BJ. On the incorporation of chemical-specific information in risk assessment. Toxicol Lett 2008;180:100-9
41. Blaauboer BJ. Biokinetic modeling and in vitro-in vivo extrapolations. J Toxicol Environ Health B Crit Rev 2010;13:242-52
42. Blaauboer BJ. The contribution of in vitro toxicity data in hazard and risk assessment: Current limitations and future perspectives. Toxicol Lett 2008;180:81-4
43. Krewski D, Andersen ME, Mantus E, Zeise L. Toxicity testing in the 21st century implications for human health risk assessment. Risk Anal 2009;29(4):474-9
44. Andersen ME. Toxicokinetics modeling and its applications in chemical risk assessment. Toxicol Lett 2003;138:9-27
45. Ambache N, Anadón A, Martínez-Larrañaga MR. Extraction and partial purification of spasmogenic substances in Auerbach's plexus. Arch Int Pharmacodyn Ther 1986;281(1):145-68
46. Anadón A, Martínez-Larrañaga MR. An inhibitory action of tetracyclines on guinea-pig myenteric plexus. Naunyn-Schmiedeberg's Arch Pharmacol 1987;335:200-3
47. Romero A, Ramos E, Castellano V, et al. Cytotoxicity induced by deltamethrin and its metabolites in SH-SY5Y cells can be differentially prevented by selected antioxidants. Toxicol In Vitro 2012;26:823-30
48. EFSA. Technical Guidance for establishing the safety of additives for the consumer. Prepared by the Panel on Additives and Products or Substances used in Animal Feed (Question No EFSA-Q-2008-406), Adopted on 16 September. EFSA J 2008;801:1-12
49. EMEA. ICH Topic S7A. Note for guidance on safety pharmacology studies for human pharmaceuticals (CPMP/ ICH/539/00) June 2001
50. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007;6:140-8